At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00867 CMS
Trading 03-02 15:00:48
14.380
-0.220
-1.51%
High14.520Low14.000Vol2.01M
Open14.300D1 Closing14.600Amplitude3.56%
Mkt Cap35.09BTradable Cap35.08BTotal Shares2.44B
T/O28.70MT/O Rate0.08%Tradable Shares2.44B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CMS Receives Initial "Buy" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth
Stock News  ·  02-25
CMS Receives Initial "Buy" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth
BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted
Reuters  ·  02-24
BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted
CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
THOMSON REUTERS  ·  02-24
CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days
THOMSON REUTERS  ·  02-24
China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days
CMS Announces Priority Review Acceptance for Ruxolitinib Phosphate Cream in China for Atopic Dermatitis
Bulletin Express  ·  02-24
CMS Announces Priority Review Acceptance for Ruxolitinib Phosphate Cream in China for Atopic Dermatitis
China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China
THOMSON REUTERS  ·  02-24
China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China
CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application
Stock News  ·  02-24
CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application
China Medical System - Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis
THOMSON REUTERS  ·  02-24
China Medical System - Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis
China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis
Reuters  ·  02-24
China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis
Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal
Simply Wall St.  ·  02-24
Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal
AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)
Simply Wall St.  ·  02-18
AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)
Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal
Simply Wall St.  ·  02-16
Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal
China Medical System Expands AI Drug Pipeline As Valuation Gap Persists
Simply Wall St.  ·  02-13
China Medical System Expands AI Drug Pipeline As Valuation Gap Persists
China Medical System Holdings Limited Announces Exclusive Distribution Agreement for Lidoderm® Lidocaine Cataplasms
Bulletin Express  ·  02-12
China Medical System Holdings Limited Announces Exclusive Distribution Agreement for Lidoderm® Lidocaine Cataplasms
CMS Secures Exclusive Distribution Rights for Lidoderm® Lidocaine Gel Patch
Stock News  ·  02-12
CMS Secures Exclusive Distribution Rights for Lidoderm® Lidocaine Gel Patch
China Medical System Signs Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms
Reuters  ·  02-12
China Medical System Signs Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms
China Medical System Holdings - Signing of Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms
THOMSON REUTERS  ·  02-12
China Medical System Holdings - Signing of Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms
Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation
Stock News  ·  02-12
Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation
BUZZ-InSilico hits fresh high on partnership deal with China Medical
Reuters  ·  02-10
BUZZ-InSilico hits fresh high on partnership deal with China Medical
Insilico Medicine Enters Drug Development Partnership With China Medical System
MT Newswires Live  ·  02-10
Insilico Medicine Enters Drug Development Partnership With China Medical System

Introduction

Company Name.
CMS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
Issue price:
--